Abstract
To improve the solubility, bioavailability and anti-tumor effect of lapatinib, lapatinib-incorporated lipid nanoparticles (LTNPs) were prepared and characterized. The particle size of LTNPs was 88.6 nm with a zeta potential of 20 mV. Laptinib was loaded into LTNPs with a non-crystal structure as determined by FT-IR. In vitro, LTNPs could be effectively uptaken into C6 glioma cells at a concentration-dependent manner. In vivo, LTNPs showed a relative higher AUC, which was 5.27- and 3.21-fold as that of Tykerb and lapatinib suspension (LTS) group. LTNPs also showed highest glioma concentration, which may benefit from the enhanced permeability and retention effect and active targeting ability. In toxicity studies, LTNPs displayed a half lethal dose over 250 mg/kg. Repeated administering 30 mg/kg of LTNPs could led to toxicity to hematology which might owe to the bovine serum albumin, a foreign protein to mice. However, there was no organic change observed through HE staining. In conclusion, LTNPs could target to glioma with high concentration and low side effect.
Keywords: Lapatinib, pharmacokinetic, tissue distribution, toxicity.
Current Pharmaceutical Biotechnology
Title:In vivo behavior and Safety of Lapatinib-Incorporated Lipid Nanoparticles
Volume: 14 Issue: 12
Author(s): Huile Gao, Chen Chen, Zhangjie Xi, Jun Chen, Qizhi Zhang, Shilei Cao and Xinguo Jiang
Affiliation:
Keywords: Lapatinib, pharmacokinetic, tissue distribution, toxicity.
Abstract: To improve the solubility, bioavailability and anti-tumor effect of lapatinib, lapatinib-incorporated lipid nanoparticles (LTNPs) were prepared and characterized. The particle size of LTNPs was 88.6 nm with a zeta potential of 20 mV. Laptinib was loaded into LTNPs with a non-crystal structure as determined by FT-IR. In vitro, LTNPs could be effectively uptaken into C6 glioma cells at a concentration-dependent manner. In vivo, LTNPs showed a relative higher AUC, which was 5.27- and 3.21-fold as that of Tykerb and lapatinib suspension (LTS) group. LTNPs also showed highest glioma concentration, which may benefit from the enhanced permeability and retention effect and active targeting ability. In toxicity studies, LTNPs displayed a half lethal dose over 250 mg/kg. Repeated administering 30 mg/kg of LTNPs could led to toxicity to hematology which might owe to the bovine serum albumin, a foreign protein to mice. However, there was no organic change observed through HE staining. In conclusion, LTNPs could target to glioma with high concentration and low side effect.
Export Options
About this article
Cite this article as:
Gao Huile, Chen Chen, Xi Zhangjie, Chen Jun, Zhang Qizhi, Cao Shilei and Jiang Xinguo, In vivo behavior and Safety of Lapatinib-Incorporated Lipid Nanoparticles, Current Pharmaceutical Biotechnology 2013; 14 (12) . https://dx.doi.org/10.2174/1389201015666140113110746
DOI https://dx.doi.org/10.2174/1389201015666140113110746 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanomedicine to Deal With Cancer Cell Biology in Multi-Drug Resistance
Mini-Reviews in Medicinal Chemistry Nano-Enabled Drug Delivery in Cancer Therapy: Literature Analysis Using the MeSH System
Pharmaceutical Nanotechnology Irinotecan for Treatment of Childhood Cancers: A Promising Therapeutic Partner
Current Cancer Therapy Reviews Anti-Cancer Cytotoxic Effects of Multiwalled Carbon Nanotubes
Current Pharmaceutical Design Identification of a Good-Prognosis IDH-Mutant-Like Population of Patients with Diffuse Gliomas
Current Molecular Medicine Subject Index to Volume 4
Current Medicinal Chemistry - Anti-Cancer Agents Macrophage Derived Cystatin B/Cathepsin B in HIV Replication and Neuropathogenesis
Current HIV Research Hypoxia-Inducible Factor-1 as Regulator of Angiogenesis in Rheumatoid Arthritis - Therapeutic Implications
Current Medicinal Chemistry Topoisomerase I Inhibitors in the Treatment of Primary CNS Malignancies: An Update on Recent Trends
Anti-Cancer Agents in Medicinal Chemistry Stability Testing During Development of Nanopharmaceuticals
Pharmaceutical Nanotechnology Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based Nanosystems)
Recent Patents on Anti-Cancer Drug Discovery Medulloblastoma: Role of Developmental Pathways, DNA Repair Signaling, and Other Players
Current Molecular Medicine Occurrence and Biological Activities of Eremophilane-type Sesquiterpenes
Mini-Reviews in Medicinal Chemistry Recent Progress on Apoptotic Activity of Triazoles
Current Drug Targets Targeting the Eph-ephrin System with Protein-Protein Interaction (PPI) Inhibitors
Current Drug Targets Flavonoid Kaempferol Inhibits the Proliferation and Survival of Human Leukemia HL60 Cells
Current Drug Therapy The Development of Ataxia Telangiectasia Mutated Kinase Inhibitors
Mini-Reviews in Medicinal Chemistry Microtubule Targeting Agents: A Benchmark in Cancer Therapy
Current Drug Therapy Preface
Current Pharmaceutical Design Doxycycline as Potential Anti-cancer Agent
Anti-Cancer Agents in Medicinal Chemistry